Kolexia
Letestu Remi Biologie médicale
Letestu Remi
Biologie médicale
Hôpital Avicenne
Bobigny, France
99 Activités
165 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie chronique lymphocytaire à cellules B Leucémies Leucémie lymphoïde Maladie résiduelle Lymphomes Leucémie B Hémoglobinurie paroxystique Hyperlymphocytose Syndromes myélodysplasiques

Collaborateurs

Voir plus
Cymbalista Florence
Cymbalista Florence
Hôpital Avicenne, Bobigny, France
Levy Vincent
Levy Vincent
Hôpital Avicenne, Bobigny, France
Lepretre Stephane
Lepretre Stephane
Centre Henri-Becquerel, Rouen, France
Leblond Véronique
Leblond Véronique
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
Abbvie
14 collaboration(s)
Dernière en 2022
A+A
2 collaboration(s)
Dernière en 2020
AstraZeneca
2 collaboration(s)
Dernière en 2022
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
Annales de biologie clinique   31 octobre 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood advances   28 juillet 2023
Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression.
Cancer gene therapy   28 mars 2023
A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
Annual Meeting Abstracts 2022   15 novembre 2022
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
Annual Meeting Abstracts 2022   15 novembre 2022
AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
Annual Meeting Abstracts 2022   15 novembre 2022
miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study.
Frontiers in immunology   17 octobre 2022
Apport de la CMF dans le diagnostic et le suivi des syndromes lymphoprolifératifs Dr Rémi LETESTU
Youtube @ SMCC Maroc   11 octobre 2022